车辆外廓尺寸-长宽高测量仪

车辆外廓尺寸-长宽高测量仪

系统介绍

根据国家标准的规定，全部货运车辆及6米以上的客车在新车上户时都要对车辆的外廓尺寸进行检测，判定车辆外廓长宽高是否超出规定的标准。本产品可对车辆外廓尺寸长宽高进行动态检测，适用于车辆管理所新车上户和社会检测站对车辆外廓尺寸长宽高的检测。全自动测量、无需人工干预，测量车辆按提示以5km/h的速度通过测量区域，采集系统高速采集车辆通过的三维数据，并自动分析出测量车辆的长宽高参数。

产品介绍

本产品采用二个高精度二维激光传感器对检测车辆的外廓进行三维图形数据点的采集、立柱光幕组对通过车辆遮挡情况的采集，综合分析出车辆外廓尺寸长宽高数据。采用的激光传感器处于国际先进水平、精度高、采集速度快，立柱光幕组由自主开发的光幕芯片组成，采集效率高。整体系统运行稳定，测量速度快，车辆通过完毕即可以实时显示测量的结果。

示意图

现场图

●环境参数

项目技术参数

环境温度0～40°

相对湿度小于95%

电源AC220v±10%，50Hz 场地尺寸15m*5m*5.5m

●测量参数

项目技术参数测量长度（mm）2000-15000 测量宽度（mm）1000-3500 测量高度（mm）1000-4500 测量误差（mm）±10/±1%

●示意图

电缆沟剖面及预埋管路示意图

光幕外廓尺寸检测线管线预埋示意图

产品检测

检测车辆在系统提示下以5km/h的速度遁过检测区域。

检测实景

检测站设备前视图

检测站设备后视图

检测线设备侧视图

龙门架和二维激光扫描仪

龙门架、光幕立柱、地磅

点阵屏、光幕立柱、地磅

Topical agents, alternative medicine, and disease severity assessment are the subjects of the latest updated set of guidelines for the management and treatment of psoriasis issued jointly by the American Academy of Dermatology and the National Psoriasis Foundation.

The guidelines, published in the Journal of the American Academy of Dermatology, focus on treatment

for adults, and follow the release of other AAD-NPF guidelines on biologics for psoriasis, psoriasis-related comorbidities, pediatric psoriasis, and phototherapy in 2019, and earlier this year, guidelines for systemic nonbiologic treatments. The latest guidelines' section on topical treatment outlines evidence for the efficacy, effectiveness, and adverse events related to topical steroids, topical tacrolimus and pimecrolimus, vitamin D analogues, tazarotene, moisturizers, salicylic acid, anthralin, coal tar, combinations with biologic agents, and combinations with nonbiologic treatments (methotrexate, cyclosporine, acitretin, and apremilast).

The guidelines noted the "key role" of topical corticosteroids in treating psoriasis "especially for localized disease," and include a review of the data on low-, moderate-, high-, and ultrahigh-potency topical steroids for psoriasis.

In general, all topical steroids can be used in combination with biologics, according to the guidelines, but the strongest recommendations based on the latest evidence include the addition of an ultra-high potency topical corticosteroid to standard dose etanercept for 12 weeks. Currently, 11 biologics are approved by the Food and Drug Administration for the treatment of psoriasis.

In addition, "while not FDA approved for psoriasis, the topical calcineurin inhibitors tacrolimus and pimecrolimus are often employed in the treatment of psoriasis," can be helpful for "thinner skin such as facial and intertriginous areas," and can be steroid sparing when used for more than 4 weeks, according to the guidelines.

Don't discount the role of patient preferences when choosing topical treatments, the authors noted. "The optimal vehicle choice is the one the patient is mostly likely to use."

The guidelines also address the evidence for effectiveness, and adverse events in the use of several alternative medicines for psoriasis including traditional Chinese medicine, and the herbal therapies aloe vera and St. John's wort, as well as the potential role of dietary supplements including fish oil, vitamin D, turmeric, and zinc in managing psoriasis, and the potential role of a gluten-free diet.

In general, research on the efficacy, effectiveness, and potential adverse effects of these strategies are limited, according to the guidelines, although many patients express interest in supplements and herbal products. For example, "Many patients ask about the overall role of vitamin D in skin health. Rather than adding oral vitamin D supplementation, topical therapy with vitamin D agents is effective for the treatment of psoriasis," the authors noted.

In addition, they noted that mind/body strategies, namely hypnosis and stress reduction or meditation techniques, have been shown to improve symptoms and can be helpful for some patients, but clinical evidence is limited.